



BIO CEO and Investor Conference to Webcast Alkermes' Corporate Presentation

February 16, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2005--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live by The Biotechnology Industry Organization (BIO) on Wednesday, February 23, 2005 at 11:00 a.m. EST. The presentation will be webcast from The Waldorf Astoria Hotel in New York and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal Consta(R) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a division of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT:

Jaren Madden
Manager, Corporate Communications
Alkermes, Inc.
(617) 583-6402